logo-loader
LON:STX

Shield Therapeutics PLC

Receive alerts
Market:
LON
Market Cap:
£217.38 m
Price
£1.86
Change
0.27%
52 weeks high
202.00
52 weeks low
27.00

Viewing results 1-25 of 35

Health

Shield Therapeutics: All eyes on the US after FDA approval

Below we take a closer look at Shield Therapeutics......

1 week, 1 day ago
Health

Shield Therapeutics PLC: FDA approves broad label for Feraccru

Shield Therapeutics (LON:STX) reports it has achieved the best possible outcome for Feraccru. The US Food & Drug Administration (FDA) has approved the treatment for a broad label to treat iron deficiency (ID) in adults, addressing a population many times wider than the iron deficiency anaemia......

3 weeks, 1 day ago
Health

Shield Therapeutics adds two-thirds to its value after receiving US approval for flagship product

The Food & Drug Administration has given what’s called broad label approval to Feraccru, which will be marketed as Accrufer in America...

3 weeks, 5 days ago
Health

Shield Therapeutics to continue “robust” defence of IP as Teva appeals Feraccru ruling

The pharmaceutical firm said no date for the appeal hearing had yet been set but it believed the initial EPO decision in its favour would be upheld...

on 3/6/19
Health

Shield Therapeutics primed for a busy year

Here we take a look under the hood of Shield Therapeutics...

on 9/5/19
Health

Shield Therapeutics PLC Heading for a US approval decision

Shield Therapeutics (LON:STX) is making excellent progress having reported two sets of new supportive clinical data on its lead product Feraccru, a low dose oral iron capsule. Feraccru is being positioned as an alternative therapy for patients with iron deficiency (ID) and iron deficiency anaemia......

on 9/5/19
Health

Shield Therapeutics wins extended approval for Feraccru in Switzerland

The company is encouraged by progress being made with regulatory authorities ahead of an expected decision from US regulators in late July...

on 24/4/19
Health

Shield Therapeutics targeting more lucrative Feraccru out-licence deals in 2019

One deal covering Europe, Australia and New Zealand helped to significantly bump up Shield’s 2018 results and the plan is to sign more lucrative agreements covering China and the US...

on 3/4/19
Health

Shield Therapeutics says European Patent Office decides in company’s favour in relation to a Feracru patent

The AIM-listed firm said that the decision, made by the EPO’s opposition division, related to patent #2 668 175, which covers a "Process for preparing an iron hydroxypyrone"...

on 15/3/19
Health

Shield Therapeutics’ Feraccru iron deficiency drug shows its mettle in head-to-head study

In the year-long phase IIIb study, Feraccru was shown to deliver “comparable” results to Ferinject, the current standard of care injection given to patients with iron deficiency...

on 4/3/19
Health

Shield Therapeutics' shares rise as it hails results of extended trial of Feraccru

The extended 52-week open-label trial showed increased haemoglobin levels ...

on 29/1/19
Health

Shield Therapeutics funded through to 2020

Shield expects the results from its head-to-head study on Feraccru this quarter and a decision by the FDA on US approval by the end of July...

on 24/1/19
Health

Shield Therapeutics appoints Karis as chairman

Karis has been on the board for three years already and chairs the remuneration committee...

on 23/1/19